[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Lee SY, Kim JJ, Lee JH, Kim YH, Rhee PL, Paik SW, Rhee JC: Healing rate of EMR-induced ulcer in relation to the duration of treatment with omeprazole. Gastrointest Endosc; 2004 Aug;60(2):213-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Healing rate of EMR-induced ulcer in relation to the duration of treatment with omeprazole.
  • BACKGROUND: Although EMR-induced ulcers heal faster and recur less often than noniatrogenic gastric ulcers, there is no consensus regarding the duration of therapy for these ulcers.
  • This study prospectively evaluated healing of EMR-induced ulcers according to the duration of omeprazole therapy.
  • METHODS: A total of 69 patients were randomly assigned, after EMR, to treatment with omeprazole (20 mg per day) for 7 days (1-week group) or with omeprazole (20 mg per day) for 28 days (4-week group).
  • Each patient kept a daily diary of drugs consumed and ulcer-related symptoms during the 4-week period after EMR.
  • In addition, no difference was observed between the two groups with respect to ulcer-related symptoms or use of additional gastric-coating medication (p=0.48).
  • CONCLUSIONS: For EMR-induced ulcer, treatment with omeprazole for 1 week is equivalent to treatment for 4 weeks.
  • Short-term therapy with omeprazole can be considered for EMR-induced ulcer.
  • [MeSH-major] Anti-Ulcer Agents / administration & dosage. Endoscopy, Gastrointestinal / adverse effects. Omeprazole / administration & dosage. Stomach Ulcer / drug therapy
  • [MeSH-minor] Adenoma / surgery. Aged. Female. Humans. Male. Prospective Studies. Stomach Neoplasms / surgery. Time Factors. Wound Healing / drug effects

  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15278047.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; KG60484QX9 / Omeprazole
  •  go-up   go-down


2. Gheorghe C, Iacob R, Dumbrava M, Becheanu G, Ionescu M: Confocal laser endomicroscopy and ultrasound endoscopy during the same endoscopic session for diagnosis and staging of gastric neoplastic lesions. Chirurgia (Bucur); 2009 Jan-Feb;104(1):17-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal laser endomicroscopy and ultrasound endoscopy during the same endoscopic session for diagnosis and staging of gastric neoplastic lesions.
  • INTRODUCTION: Confocal LASER endomicroscopy (CLE) is a newly developed endoscopic technique which allows subsurface in vivo histological assessment during ongoing endoscopy and targeted biopsies.
  • We describe for the first time the use of both techniques during the same endoscopic session, in a pilot study, in order to increase the diagnostic yield of histological assessment and provide the staging of the gastric neoplastic lesions thus decreasing the time to therapeutic decision.
  • The indication of CLE/EUS exploration was the presence of a gastric polypoid lesion in 37% of cases, atypical gastric ulcer in 27% of patients, gastric lymphoma 18%, suspicion of gastric cancer recurrence after resection 9% and infiltrating type gastric cancer 9%.
  • Histological assessment after targeted biopsy has established the diagnosis of gastric adenocarcinoma in 55% of cases, gastric lymphoma in 18% of cases, gastric adenoma, gastric GIST and gastric foveolar hyperplasia in 9% of cases respectively.
  • In 2 patients - one case with suspected recurrent gastric cancer after surgery and one case of gastric lymphoma, CLE has indicated normal gastric mucosa.
  • The EUS evaluation showed in one gastric lymphoma patient a lesion interesting the mucosa and submucosa with regional adenopathy and a submucosal lesion with regional adenopathy in the other gastric lymphoma case.
  • The therapeutic decision was surgery in 73% of cases, chemotherapy and follow-up in 18% of cases and follow-up in 9% of cases.
  • CONCLUSION: CLE and EUS can be successfully associated during the same endoscopic session, for upper GI neoplastic lesions allowing targeted biopsies for histological assessment and disease staging for optimal therapeutic decision.
  • [MeSH-major] Endosonography. Microscopy, Confocal. Stomach Neoplasms / pathology. Stomach Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Gastric Mucosa / pathology. Gastric Mucosa / ultrasonography. Humans. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19388564.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


3. Chang HJ, Oh SN, Park MY, Rha SE, Choi BG: Fraudulent retouching of digital radiographic images--a potential risk. Clin Radiol; 2010 Dec;65(12):967-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Ten representative key images were selected of aortic dissection, hepatocellular carcinoma, renal cell carcinoma, colon cancer, liver metastasis, hepatic cyst, gallbladder stones, splenic artery aneurysm, adrenal adenoma, and stomach cancer from abdominal computed tomography (CT) imaging performed in 2008.
  • The time to complete retouching was recorded for each image.
  • Radiologists were requested to make a diagnosis for the 10 images, and were then asked to identify possible retouched images.
  • The time taken to reach a decision in each case was recorded.
  • RESULTS: The time to complete retouching was 15.2±3.15 min.
  • None of the reviewers recognized that some images were retouched during diagnosis.
  • The rate of correct diagnosis was 90% (range 71.7-100%).
  • After reviewers were informed of possible image retouching, the detection rate of retouched images was 50% (40-58.3%).
  • There was no significant difference between residents and attending radiologists in the detection rate of retouched images (p=0.786).
  • The time to diagnosis and the time to detection of the retouched images were 15 (14-17) and 6 (5-7) min, respectively.
  • [MeSH-minor] Deception. Fraud. Humans. Insurance Claim Reporting / legislation & jurisprudence. Internship and Residency. Radiology. Republic of Korea. Software. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 21070899.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Saito K, Arai K, Mori M, Kobayashi R, Ohki I: Effect of Helicobacter pylori eradication on malignant transformation of gastric adenoma. Gastrointest Endosc; 2000 Jul;52(1):27-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Helicobacter pylori eradication on malignant transformation of gastric adenoma.
  • BACKGROUND: A nonrandomized trial of Helicobacter pylori eradication was conducted in patients with endoscopically diagnosed gastric adenoma to determine the long-term effect of antimicrobial treatment on progression of the adenoma.
  • METHODS: Of 64 patients with an endoscopically diagnosed gastric adenoma and H pylori infection, 32 were treated with omeprazole and antibiotics to eradicate the infection, and 32 were not.
  • RESULTS: During 2 years of follow-up, 4 (12.5%) of the 32 patients in the untreated group developed an early stage, intestinal-type gastric cancer, whereas no gastric cancer was found in the 32 patients in the treated group.
  • CONCLUSION: H Pylori eradication may inhibit progression of gastric adenoma to carcinoma.
  • [MeSH-major] Adenoma / pathology. Amoxicillin / administration & dosage. Cell Transformation, Neoplastic / pathology. Clarithromycin / administration & dosage. Helicobacter Infections / drug therapy. Helicobacter pylori / drug effects. Omeprazole / administration & dosage. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma / diagnosis. Carcinoma / epidemiology. Carcinoma / microbiology. Carcinoma / pathology. Drug Therapy, Combination. Female. Gastric Mucosa / pathology. Gastroscopy. Humans. Incidence. Male. Probability. Reference Values. Statistics, Nonparametric. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • Hazardous Substances Data Bank. Clarithromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10882958.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 804826J2HU / Amoxicillin; H1250JIK0A / Clarithromycin; KG60484QX9 / Omeprazole
  •  go-up   go-down


5. Abela JE, Wright DM, Hennessy A, Roberts F, Anderson JR: Chemotherapy induced carcinoma-adenoma regression in the caecum. J Clin Pathol; 2009 Mar;62(3):282-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy induced carcinoma-adenoma regression in the caecum.
  • The case of a male patient with synchronous oesophago-gastric junction (OGJ) and caecal adenocarcinomas is reported.
  • His management is described, particularly the administration of neoadjuvant chemotherapy targeting his upper gastrointestinal cancer.
  • Histopathological examination of the surgical specimen confirmed the OGJ cancer but only identified a caecal adenoma.
  • This is believed to be the first description of chemotherapy induced reversal of the adenoma-carcinoma sequence.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenoma / pathology. Cecal Neoplasms / drug therapy. Neoplasms, Multiple Primary / drug therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Esophagogastric Junction. Humans. Male. Neoadjuvant Therapy. Remission Induction. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251957.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Uesato M, Nabeya Y, Akai T, Inoue M, Watanabe Y, Kawahira H, Mamiya T, Ohta Y, Motojima R, Kagaya A, Muto Y, Hayashi H, Matsubara H: Salivary amylase activity is useful for assessing perioperative stress in response to pain in patients undergoing endoscopic submucosal dissection of gastric tumors under deep sedation. Gastric Cancer; 2010 Jun;13(2):84-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary amylase activity is useful for assessing perioperative stress in response to pain in patients undergoing endoscopic submucosal dissection of gastric tumors under deep sedation.
  • BACKGROUND: Although endoscopic submucosal dissection (ESD) for patients with gastric tumors under the conditions of unconsciousness is considered to be minimally invasive, no objective assessment of the perioperative stress of ESD has yet been conducted.
  • METHODS: A total of 40 patients with gastric cancers/adenomas removed by ESD under general anesthesia (GA; n = 20) and under deep sedation (DS; n = 20) were enrolled. sAMY was measured using the enzyme analysis equipment, sAMY Monitor (NIPRO, Osaka, Japan) during the perioperative period of the ESD.
  • [MeSH-major] Amylases / metabolism. Saliva / enzymology. Stomach Neoplasms / surgery. Stress, Physiological
  • [MeSH-minor] Adenoma / pathology. Adenoma / surgery. Aged. Analgesics / therapeutic use. Anesthesia, General. Female. Gastric Mucosa / surgery. Gastroscopy / adverse effects. Humans. Male. Middle Aged. Pain / drug therapy. Pain / enzymology. Pain / etiology. Perioperative Care / methods. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anesthesiology. 2002 Apr;96(4):1004-17 [11964611.001]
  • [Cites] Reg Anesth Pain Med. 2007 Mar-Apr;32(2):120-3 [17350522.001]
  • [Cites] Anesth Analg. 2005 Dec;101(6):1873-6 [16301277.001]
  • [Cites] Biosens Bioelectron. 2006 Jan 15;21(7):1007-14 [15871919.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1032:258-63 [15677423.001]
  • [Cites] Anesthesiology. 1998 Mar;88(3):642-50 [9523807.001]
  • [Cites] Clin Physiol. 1996 Jul;16(4):433-48 [8842578.001]
  • [Cites] Arch Oral Biol. 2004 Dec;49(12):963-8 [15485637.001]
  • [Cites] Psychoneuroendocrinology. 2006 Jan;31(1):49-58 [16002223.001]
  • [Cites] Gastric Cancer. 2007;10(1):1-11 [17334711.001]
  • [Cites] Int J Psychophysiol. 2000 Apr;36(1):59-68 [10700623.001]
  • [Cites] Gastrointest Endosc. 1995 Dec;42(6):626-9 [8674947.001]
  • [Cites] Anesthesiology. 1997 Apr;86(4):836-47 [9105228.001]
  • [Cites] Arch Oral Biol. 1974 Sep;19(9):747-52 [4533726.001]
  • [Cites] Hepatogastroenterology. 2005 May-Jun;52(63):954-8 [15966240.001]
  • [Cites] Biosens Bioelectron. 2004 Oct 15;20(3):491-7 [15494230.001]
  • [Cites] Neuropsychobiology. 1989;22(3):150-69 [2485862.001]
  • [Cites] J Med Invest. 2007 Feb;54(1-2):140-5 [17380025.001]
  • [Cites] Psychoneuroendocrinology. 2006 Jan;31(1):137-41 [16046076.001]
  • [Cites] Gastrointest Endosc. 2005 Dec;62(6):860-5 [16301026.001]
  • (PMID = 20602194.001).
  • [ISSN] 1436-3305
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Analgesics; EC 3.2.1.- / Amylases
  •  go-up   go-down


7. Cavallaro G, Albanese V, Taranto F, Pustorino S, Baldari S: Brunner's adenoma, esophageal reflux and gastric ulcer. A case report. Chir Ital; 2000 Nov-Dec;52(6):703-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brunner's adenoma, esophageal reflux and gastric ulcer. A case report.
  • In this work the authors report a clinical case of Brunner's adenoma, which was responsible for the onset of other pathologies in the upper gastrointestinal tract, such as gastroesophageal reflux (GER), esophagitis and ulcerations of the antral mucosa.
  • The preoperative diagnostic procedure (endoscopy, esophageal manometry, gastric emptying) and the follow-up at 3, 6 and 12 months from the surgery confirmed the relationship between the Brunner's adenoma and the alterations of the lower esophageal sphyncter (LES) tone and the gastric emptying.
  • [MeSH-minor] Aged. Female. Gastroesophageal Reflux / complications. Gastroesophageal Reflux / drug therapy. Humans. Stomach Ulcer / complications

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11200007.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


8. Ramser KL, Sprabery LR, Hamann GL, George CM, Will A: Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change. J Manag Care Pharm; 2009 May;15(4):344-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
  • In order to obtain an approved PA for a PPI, the patient was required to have either (a) a diagnosis of erosive esophagitis, Barrett's esophagus, Schatzki's ring, a pathological hypersecretory condition (e.g., Zollinger-Ellison syndrome, multiple endocrine adenoma), grade III-IV gastroesophageal reflux disease (GERD), non-steroidal anti-inflammatory drug gastropathy, significant gastrointestinal bleed; or (b) another indication for acid suppression therapy (e.g., GERD, hyperacidity in cystic fibrosis, gastric or duodenal ulcer, gastroparesis) with a history of failure of prior therapy with a histamine-2 receptor antagonist (H2-blocker).
  • OBJECTIVE: To (a) describe the process used by an internal medicine clinic to ensure that patients requiring acid suppression therapy received appropriate treatment according to revised TennCare formulary criteria without unnecessary interruption of therapy, and (b) assess self-reported symptom control 8 months after intervention in the patients who either discontinued therapy or stepped-down to H2-blocker therapy.
  • A clinical pharmacist and an internal medicine physician collaborated to develop a protocol for adjusting acid suppression therapy.
  • A clinical pharmacist reviewed medical records for all patients identified to verify indications for acid suppression therapy and review medication history.
  • Patient telephone interviews were also conducted for patients whose indication or medication history could not be determined by chart review.
  • Patients who met TennCare criteria for PPI therapy were continued on PPI therapy after a PA was obtained (PA group).
  • Patients who had a documented indication for acid suppression therapy but did not meet the PA criteria for PPI therapy were changed to H2-blocker therapy (step-down group).
  • Patients without a documented indication for acid suppression therapy were discontinued from acid suppression therapy (discontinue therapy group).
  • A follow-up chart review and patient telephone interview were conducted 8 months after the intervention for patients in the step-down and discontinue therapy groups.
  • The purpose of this follow-up review was to determine (a) the proportion of patients who were taking acid suppression therapy, (b) the type of acid suppression therapy (PPI or H2-blocker), and (c) self-report of adequate control of symptoms (defined as symptoms once weekly or less).
  • RESULTS: Of 135 TennCare beneficiaries who were active patients of the internal medicine clinic and received a prescription from the outpatient pharmacy for PPI therapy (pantoprazole) between April 20 and June 20, 2005, 6 patients were excluded because they reported stopping PPI therapy on their own.
  • Of the remaining 129 patients, 18 (14.0%) did not have an indication for PPI therapy and acid suppression therapy was discontinued (discontinue therapy group), 40 (31.0%) met the TennCare PA criteria for continuation of PPI therapy (PA group), and 71 (55.0%) did not meet the TennCare PA criteria and were stepped down to a H2-blocker (step-down group).
  • At the 8-month follow-up, acid suppression therapy was assessed in 68 patients (21 patients were lost to follow-up): 13 patients (19.1%) had resumed PPI therapy; 38 (55.9%) were using an H2-blocker; and 17 (25.0%) were not using acid suppression therapy.
  • Telephone interviews were completed for 45 of the 75 patients in the step-down and discontinue therapy groups who did not receive an escalation in acid suppression therapy after the initial intervention (i.e., who did not make a change from H2-blocker therapy to PPI therapy or from no acid suppression therapy to H2-blocker or PPI therapy).
  • CONCLUSIONS: After a proactive collaboration between physicians and clinical pharmacists in response to changes in TennCare formulary criteria for PPIs, more than one-half of patients were stepped down to H2-blocker therapy, and 14% were discontinued from acid suppression therapy.
  • Among the step-down or therapy discontinuation patients for whom data were available at the 8-month follow-up, 81% were still using either an H2-blocker or no acid suppressing therapy at all, and 19% had resumed PPI use.
  • [MeSH-major] Formularies, Hospital. Gastrointestinal Diseases / drug therapy. Health Plan Implementation / statistics & numerical data. Histamine H2 Antagonists / therapeutic use. Medicaid. Practice Patterns, Physicians' / statistics & numerical data. Proton Pump Inhibitors / therapeutic use. Withholding Treatment

  • MedlinePlus Health Information. consumer health - Medicaid.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19422274.001).
  • [ISSN] 1083-4087
  • [Journal-full-title] Journal of managed care pharmacy : JMCP
  • [ISO-abbreviation] J Manag Care Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histamine H2 Antagonists; 0 / Proton Pump Inhibitors
  •  go-up   go-down


9. Reichart M, Busch OR, Bruno MJ, Van Lanschot JJ: Black esophagus: a view in the dark. Dis Esophagus; 2000;13(4):311-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 73-year-old man had a low anterior resection for a villous adenoma in the rectosigmoid.
  • On the 4th day after surgery, he suddenly developed severe interscapular pain.
  • With conservative treatment, including proton pump inhibition, he recovered completely.
  • We hypothesize that a transient gastric outlet obstruction and massive gastroesophageal reflux played a significant role in the etiology of this rare and alarming, but, in this case, completely reversible, syndrome.

  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • Hazardous Substances Data Bank. SUCRALFATE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11284980.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Proton Pump Inhibitors; 54182-58-0 / Sucralfate; KG60484QX9 / Omeprazole
  •  go-up   go-down


10. Alroy J, Ucci AA, Azabdoaftari G, Banner BF, Cheville JC: Expression of CD3 antigens in renal tubule epithelium and renal oncocytomas. Pathol Res Pract; 2005;201(12):803-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD3 antigens in renal tubule epithelium and renal oncocytomas.
  • CD3 antigen, formerly thought to be specific for T lymphocytes, has been identified in Purkinje cells of the cerebellum and gastric parietal cells in several species, including humans.
  • This subunit has a role in signal transduction in T lymphocytes and possibly other types of cells.
  • CD3 expression was strong in normal proximal and distal tubular epithelium in most species and in renal oncocytomas, weak in chromophobe carcinoma, and negative in clear cell carcinomas, in papillary renal cell carcinoma, and in a transitional cell carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / metabolism. Antigens, CD3 / metabolism. Kidney Neoplasms / metabolism. Kidney Tubules / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308105.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD3
  •  go-up   go-down


11. Yumiba T, Ito T, Ikushima H, Taniguchi E, Inoue Y, Nishida T, Kitagawa T, Nishikawa K, Ohashi S, Matsuda H: Effect of mucosal suture on the healing of mucosal defect in laparoscopic intragastric surgery. Gastric Cancer; 2003;6(2):96-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The efficacy of mucosal suturing for the healing of a mucosal defect in laparoscopic intragastric surgery (LIGS) for gastric lesions is not yet known.
  • METHODS: We prospectively studied ten patients who underwent mucosal resection by LIGS for gastric tumors: four patients with early gastric cancer and six with gastric adenoma.
  • The medication cost (H2-blocker) in group I was significantly lower than that in group II.
  • CONCLUSION: Mucosal defect suturing after mucosal resection by LIGS promotes more rapid healing of mucosal defects and reduces drug costs for patients.
  • [MeSH-major] Gastric Mucosa / surgery. Laparoscopy. Suture Techniques. Wound Healing / physiology
  • [MeSH-minor] Adenoma / physiopathology. Adenoma / surgery. Aged. Anti-Ulcer Agents / therapeutic use. Endoscopy, Gastrointestinal. Female. Histamine H2 Antagonists / therapeutic use. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / diagnosis. Postoperative Complications / drug therapy. Postoperative Complications / physiopathology. Prospective Studies. Randomized Controlled Trials as Topic. Stomach Neoplasms / physiopathology. Stomach Neoplasms / surgery. Stomach Ulcer / diagnosis. Stomach Ulcer / drug therapy. Stomach Ulcer / physiopathology. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12861400.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Histamine H2 Antagonists
  •  go-up   go-down


12. Lee SH, Cheon JH, Kim JH, Park JP, Lee SK, Lee YC: [Non-healing iatrogenic gastric ulcers after endoscopic mucosal resection for gastric epithelial neoplasia: report of two cases]. Korean J Gastroenterol; 2008 Feb;51(2):127-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-healing iatrogenic gastric ulcers after endoscopic mucosal resection for gastric epithelial neoplasia: report of two cases].
  • Endoscopic mucosal resection (EMR) is widely accepted as a standard treatment for early gastric cancer or gastric adenoma.
  • Although the characteristics of EMR-induced ulceration are not fully understood, this type of ulcer is thought to heal faster and to recur less often than non-iatrogenic gastric ulcer.
  • Herein, we report two cases of non-healing persistent gastric ulcers after EMR.
  • One is a case of gastric carcinoma which developed at the same site of previous EMR site for the low grade dysplasia.
  • The other is a case in which persistent EMR-induced ulcer was healed in the long run after Helicobacter pylori eradication therapy.
  • [MeSH-major] Gastric Mucosa / surgery. Stomach Neoplasms / surgery. Stomach Ulcer / etiology
  • [MeSH-minor] Aged. Endoscopy, Gastrointestinal. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans. Iatrogenic Disease. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349575.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


13. Watanabe Y, Kato N, Maehata T, Okamoto M, Tsuda T, Hattori S, Yamauchi S, Fujita K, Baba S, Nakaya S, Inaba H, Kitajima S, Suzuki M, Niwa H, Itoh F: Safer endoscopic gastric mucosal resection: preoperative proton pump inhibitor administration. J Gastroenterol Hepatol; 2006 Nov;21(11):1675-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safer endoscopic gastric mucosal resection: preoperative proton pump inhibitor administration.
  • Proton pump inhibitors (PPI) are potent suppressors of gastric acid; however, PPI need to be continuously administered orally for several days, and thus initial effects may be insufficient if PPI is only administered immediately after EMR.
  • [MeSH-major] Adenoma / surgery. Anti-Ulcer Agents / administration & dosage. Gastric Mucosa / surgery. Gastroscopy. Hemostasis, Surgical / methods. Preoperative Care. Proton Pump Inhibitors. Stomach Neoplasms / surgery
  • [MeSH-minor] Administration, Oral. Aged. Blood Loss, Surgical / prevention & control. Breath Tests. Female. Humans. Hydrogen-Ion Concentration. Male. Postoperative Hemorrhage / prevention & control. Stomach Ulcer / drug therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984588.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Proton Pump Inhibitors
  •  go-up   go-down


14. Takhar AS, Eremin O, Watson SA: The role of gastrin in colorectal carcinogenesis. Surgeon; 2004 Oct;2(5):251-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently, treatment options for this debilitating disease are limited and surgical resection is the only curative treatment available.
  • Despite rapid advances in surgery, as well as in adjuvant therapies such as radiotherapy and chemotherapy, there has been only a relatively modest improvement in mortality.
  • The majority of colorectal cancers are epithelial-derived adenocarcinomas and arise from benign adenomas through the gain of mutations in key genes.
  • Gastrin, an important polypeptide hormone, responsible for gastric acid secretion has been found to be involved in tumourigenesis in the gastrointestinal tract.
  • In colonic tumourigenesis, gene expression of both gastrin and the gastrin/CCK-2 receptor is activated within epithelial cells at an early stage of the adenoma-carcinoma sequence.
  • This review details the role played by gastrin in the adenoma-carcinoma sequence of colorectal carcinogenesis.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15570843.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Gastrins; 9011-97-6 / Cholecystokinin
  • [Number-of-references] 58
  •  go-up   go-down


15. Miehlke S, Kirsch C, Dragosics B, Gschwantler M, Oberhuber G, Antos D, Dite P, Läuter J, Labenz J, Leodolter A, Malfertheiner P, Neubauer A, Ehninger G, Stolte M, Bayerdörffer E: Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). World J Gastroenterol; 2001 Apr;7(2):243-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study).
  • AIM: To test the hypothesis that Helicobacter pylori eradication alone can reduce the incidence of gastric cancer in a subgroup of individuals with an increased risk for this fatal disease.
  • Men between 55 and 65 years of age with a gastric cancer phenotype of Helicobacter pylori gastritis are randomized to receive a 7 day course of omeprazole 2 X 20mg, clarithromycin 2 X 500mg, and amoxicillin 2 X 1g for 7 days, or omeprazole 2 X 20mg plus placebo.
  • Follow-up endoscopy is scheduled 3 months after therapy, and thereafter in one-year intervals.
  • Predefined study endpoints are gastric cancer, precancerous lesions (dysplasia, adenoma), other cancers, and death.
  • RESULTS: Since March 1998, 1524 target patients have been screened, 279 patients (18.3%) had a corpus dominant type of H. pylori gastritis, and 167 of those were randomized (58.8%).
  • In the active treatment group (r = 86), H. pylori infection infection was cured in 88.9% of patients.
  • Currently, the cumulative follow-up time is 3046 months (253.38 patient years, median follow up 16 months).
  • So far, none of the patients developed gastric cancer or any precancerous lesion.
  • Three (1.8%) patients reached study endpoints other than gastric cancer.
  • CONCLUSION: Among men between 55 and 65 years of age, the gastric cancer phenotype of H. pylori gastritis appears to be more common than expected.
  • [MeSH-major] Amoxicillin / therapeutic use. Anti-Bacterial Agents / therapeutic use. Clarithromycin / therapeutic use. Gastritis / drug therapy. Gastrointestinal Agents / therapeutic use. Helicobacter Infections / drug therapy. Helicobacter pylori. Omeprazole / therapeutic use. Stomach Neoplasms / microbiology. Stomach Neoplasms / prevention & control
  • [MeSH-minor] Drug Therapy, Combination. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • Hazardous Substances Data Bank. Clarithromycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11819768.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Gastrointestinal Agents; 804826J2HU / Amoxicillin; H1250JIK0A / Clarithromycin; KG60484QX9 / Omeprazole
  • [Other-IDs] NLM/ PMC4723530
  •  go-up   go-down






Advertisement